Literature DB >> 7349895

Kinetics of cyclophosphamide biotransformation in vivo.

B E Domeyer, N E Sladek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7349895

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  12 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  The effect of cimetidine on cyclophosphamide metabolism in rabbits.

Authors:  L B Anthony; Q C Long; R F Struck; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).

Authors:  D S Alberts; J G Einspahr; R Struck; G Bignami; L Young; E A Surwit; S E Salmon
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

Authors:  R N Harris; P J Basseches; P L Appel; A M Durski; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Responses of a murine B16 melanoma to pharmacotherapy studied and compared with different assay systems.

Authors:  Y Kuwashima; O Matsubara; T Kasuga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 10.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.